CVS Health
CVS
88.84
-1.43
-1.58%
CVS Health
US · CVS
#129 by market cap
Listed 1970
-1.58%
88.84
-1.43
-1.58%
Collector offline (last heartbeat: 83788s ago)
· 2026-09-18 20:02
Pre-market
89.83
-0.48%
After-hours
89.05
+0.24%
Overnight
90.09
-0.20%
- Market cap
- 113.62B
- P/E (TTM)i
- 23.44
- P/Bi
- 1.43
- EPSi
- 1.39
- Div yieldi
- 2.99%
- 52W posi
- 49%
Reader sentiment
Are you bullish or bearish on CVS?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Latest year +7.85% YoY
Margins
- Gross margin
- 13.77%
- Operating margin
- 2.58%
- Net margin
- 0.44%
Key ratios & quality
- Enterprise valuei
- 169.33B
- Altman Z-Scorei
- 2.38
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.38, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 194.58B | 256.78B | 268.71B | 292.11B | 322.47B | 357.78B | 372.81B | 402.07B |
| Gross profit | 31.54B | 45.53B | 49.05B | 52.12B | 54.50B | 54.43B | 51.40B | 55.36B |
| Selling & admin expenses | -- | -- | -- | -- | -- | -- | -- | -- |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 10.17B | 12.22B | 13.91B | 15.10B | 16.29B | 14.60B | 9.70B | 10.39B |
| Pretax profit | 1.41B | 9.00B | 9.77B | 10.54B | 5.84B | 11.17B | 6.15B | 2.14B |
| Tax | 2.00B | 2.37B | 2.57B | 2.55B | 1.51B | 2.81B | 1.56B | 408.00M |
| Net profit | -596.00M | 6.63B | 7.19B | 7.99B | 4.33B | 8.37B | 4.59B | 1.73B |
| Basic EPS | -1 | 5 | 5 | 6 | 3 | 6 | 4 | 1 |
| Diluted EPS | -0.57 | 5.08 | 5.46 | 6.02 | 3.26 | 6.47 | 3.66 | 1.39 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 94.59B | 98.92B | 102.87B | 105.69B | 100.43B | 106.10B |
| Gross profit | 14.40B | 13.59B | 13.81B | 13.57B | 15.62B | 15.75B |
| Selling & admin expenses | -- | -- | -- | -- | -- | -- |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 3.37B | 2.38B | 2.52B | 2.11B | 4.68B | 4.70B |
| Pretax profit | 2.62B | 1.65B | -3.48B | 1.35B | 3.94B | 3.98B |
| Tax | 835.00M | 634.00M | 508.00M | -1.57B | 981.00M | 982.00M |
| Net profit | 1.78B | 1.01B | -3.99B | 2.92B | 2.96B | 3.00B |
| Basic EPS | 1 | 1 | -3 | 2 | 2 | 2 |
| Diluted EPS | 1.41 | 0.80 | -3.13 | 2.30 | 2.30 | 2.31 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 45.24B | 50.30B | 56.37B | 60.01B | 65.63B | 67.86B | 68.65B | 74.71B |
| Cash & ST investments | 6.58B | 8.06B | 10.85B | 12.53B | 15.72B | 11.46B | 10.99B | 10.60B |
| Inventory | 16.45B | 17.52B | 18.50B | 17.76B | 19.09B | 18.03B | 18.11B | 19.25B |
| Total assets | 196.46B | 222.45B | 230.72B | 233.00B | 228.28B | 249.73B | 253.22B | 253.54B |
| Total current liabilities | 44.01B | 53.30B | 62.02B | 67.81B | 69.42B | 79.19B | 84.61B | 88.69B |
| Short-term debt | 1.99B | 5.38B | 7.08B | 5.85B | 3.46B | 4.71B | 7.49B | 5.81B |
| Long-term debt | 71.44B | 64.70B | 59.21B | 51.97B | 50.48B | 58.64B | 60.53B | 60.50B |
| Total liabilities | 137,913,000,000.00 | 158,279,000,000.00 | 161,014,000,000.00 | 157,618,000,000.00 | 156,506,000,000.00 | 173,092,000,000.00 | 177,485,000,000.00 | 178,156,000,000.00 |
| Total equity | 58.54B | 64.17B | 69.70B | 75.38B | 71.77B | 76.64B | 75.73B | 75.38B |
| Retained earnings | 40.91B | 45.11B | 49.64B | 54.91B | 56.40B | 61.60B | 62.84B | 61.20B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 73.19B | 75.65B | 77.11B | 74.71B | 74.82B | 75.35B |
| Cash & ST investments | 12.65B | 14.17B | 11.23B | 10.60B | 11.80B | 13.96B |
| Inventory | 17.39B | 17.45B | 18.96B | 19.25B | 17.77B | 17.62B |
| Total assets | 255.59B | 258.34B | 255.33B | 253.54B | 252.97B | 253.77B |
| Total current liabilities | 88.96B | 94.16B | 92.70B | 88.69B | 86.41B | 87.04B |
| Short-term debt | 7.58B | 11.11B | 7.24B | 5.81B | 4.48B | 3.87B |
| Long-term debt | 59.04B | 57.29B | 60.51B | 60.50B | 60.53B | 59.45B |
| Total liabilities | 178,475,000,000.00 | 180,792,000,000.00 | 182,217,000,000.00 | 178,156,000,000.00 | 175,337,000,000.00 | 173,869,000,000.00 |
| Total equity | 77.11B | 77.55B | 73.11B | 75.38B | 77.64B | 79.90B |
| Retained earnings | 63.77B | 63.94B | 59.11B | 61.20B | 63.28B | 65.40B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 8.87B | 12.85B | 15.87B | 18.27B | 16.18B | 13.43B | 9.11B | 10.64B |
| Depreciation & amortization | 2.72B | 4.37B | 4.44B | 4.49B | 4.22B | 4.37B | 4.60B | 4.61B |
| Free cash flow | 6.83B | 10.39B | 13.43B | 15.75B | 13.45B | 10.40B | 6.33B | 7.81B |
| Dividends paid | -2.04B | -2.60B | -2.62B | -2.63B | -2.91B | -3.13B | -3.37B | -3.40B |
| Stock buybacks / issuance | -- | -- | -- | 0 | -3.50B | -2.01B | -3.02B | 0 |
| Ending cash balance | 4.30B | 8.41B | 11.04B | 12.69B | 13.31B | 8.53B | 8.88B | 8.71B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 4.56B | 1.90B | 796.00M | 3.39B | 4.25B | 6.35B |
| Depreciation & amortization | 1.15B | 1.17B | 1.13B | 1.15B | 1.12B | 1.13B |
| Free cash flow | 3.81B | 1.29B | 98.00M | 2.61B | 3.40B | 5.65B |
| Dividends paid | -840.00M | -866.00M | -846.00M | -845.00M | -847.00M | -878.00M |
| Stock buybacks / issuance | 0 | 0 | 0 | 0 | -- | -- |
| Ending cash balance | 10.35B | 12.03B | 9.35B | 8.71B | 9.77B | 11.54B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -1.24 | 10.87 | 10.78 | 10.95 | 5.68 | 11.32 | 6.07 | 2.35 |
| ROA %i | -0.41 | 3.17 | 3.17 | 3.41 | 1.80 | 3.49 | 1.83 | 0.70 |
| ROIC %i | 1.34 | 6.24 | 6.07 | 6.42 | 3.99 | 6.95 | 4.34 | 2.74 |
| 5-year avg ROE %i | 11.41 | 11.14 | 10.51 | 9.85 | 7.47 | 9.98 | 9.02 | 7.33 |
| EBIT margin %i | 2.07 | 4.69 | 4.72 | 4.42 | 2.45 | 3.87 | 2.44 | 1.31 |
| FCF / sales %i | 3.51 | 4.05 | 5.00 | 5.39 | 4.17 | 2.91 | 1.70 | 1.94 |
| Current ratioi | 1.03 | 0.94 | 0.91 | 0.88 | 0.95 | 0.86 | 0.81 | 0.84 |
| Quick ratioi | 0.55 | 0.52 | 0.53 | 0.55 | 0.62 | 0.59 | 0.56 | 0.57 |
| Debt / assetsi | 126.11 | 139.36 | 122.56 | 101.23 | 98.97 | 103.82 | 109.74 | 106.30 |
| LT debt / equityi | 122.70 | 130.94 | 112.36 | 93.44 | 94.13 | 97.66 | 99.82 | 98.58 |
| Interest coveragei | 1.54 | 3.96 | 4.36 | 5.16 | 3.46 | 5.20 | 3.08 | 1.68 |
| Revenue CAGR (3Y) %i | 8.27 | 13.09 | 13.29 | 14.50 | 7.89 | 10.01 | 8.47 | 7.63 |
| Net income CAGR (3Y) %i | -- | 7.66 | 2.73 | -- | -13.38 | 5.14 | -16.76 | -25.70 |
| FCF CAGR (3Y) %i | 3.42 | 9.49 | 30.16 | 32.11 | 8.98 | -8.18 | -26.21 | -16.58 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 7.00 | 5.95 | 0.63 | 2.35 | 3.80 | 6.23 |
| ROA %i | 2.09 | 1.77 | 0.18 | 0.70 | 1.15 | 1.91 |
| ROIC %i | 4.77 | 4.17 | 1.86 | 2.74 | 3.53 | 4.75 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 2.69 | 2.47 | 1.52 | 1.31 | 1.61 | 2.14 |
| FCF / sales %i | 1.57 | 1.24 | 1.60 | 1.94 | 1.81 | 2.83 |
| Current ratioi | 0.82 | 0.80 | 0.83 | 0.84 | 0.87 | 0.87 |
| Quick ratioi | 0.59 | 0.58 | 0.59 | 0.57 | 0.61 | 0.62 |
| Debt / assetsi | 105.57 | 106.91 | 112.10 | 106.30 | 101.15 | 95.74 |
| LT debt / equityi | 95.72 | 92.55 | 102.18 | 98.58 | 95.36 | 90.88 |
| Interest coveragei | 3.37 | 3.12 | 1.94 | 1.68 | 2.11 | 2.87 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Health services48.82%
Health Care Benefits35.38%
Pharmacy & Consumer Wellness31.87%
Corporate/other0.14%
Quote time 2026-09-18 20:02:32 · For reference only, not investment advice.